CDXC
Price
$5.94
Change
+$0.29 (+5.13%)
Updated
Jan 17 closing price
Capitalization
453.72M
46 days until earnings call
ORMP
Price
$2.28
Change
-$0.04 (-1.72%)
Updated
Jan 17 closing price
Capitalization
91.91M
39 days until earnings call
Ad is loading...

CDXC vs ORMP

Header iconCDXC vs ORMP Comparison
Open Charts CDXC vs ORMPBanner chart's image
ChromaDex
Price$5.94
Change+$0.29 (+5.13%)
Volume$364.99K
Capitalization453.72M
Oramed Pharmaceuticals
Price$2.28
Change-$0.04 (-1.72%)
Volume$137.56K
Capitalization91.91M
CDXC vs ORMP Comparison Chart
Loading...
CDXC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDXC vs. ORMP commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXC is a Hold and ORMP is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (CDXC: $5.94 vs. ORMP: $2.28)
Brand notoriety: CDXC and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXC: 56% vs. ORMP: 80%
Market capitalization -- CDXC: $453.72M vs. ORMP: $91.91M
CDXC [@Biotechnology] is valued at $453.72M. ORMP’s [@Biotechnology] market capitalization is $91.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXC’s FA Score shows that 0 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • CDXC’s FA Score: 0 green, 5 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, CDXC is a better buy in the long-term than ORMP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXC’s TA Score shows that 4 TA indicator(s) are bullish while ORMP’s TA Score has 3 bullish TA indicator(s).

  • CDXC’s TA Score: 4 bullish, 3 bearish.
  • ORMP’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, CDXC is a better buy in the short-term than ORMP.

Price Growth

CDXC (@Biotechnology) experienced а +12.71% price change this week, while ORMP (@Biotechnology) price change was -4.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

CDXC is expected to report earnings on May 08, 2025.

ORMP is expected to report earnings on May 28, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDXC($454M) has a higher market cap than ORMP($91.9M). CDXC has higher P/E ratio than ORMP: CDXC (297.00) vs ORMP (20.73). CDXC YTD gains are higher at: 11.970 vs. ORMP (-5.785). ORMP has higher annual earnings (EBITDA): 9.44M vs. CDXC (1.95M). ORMP has more cash in the bank: 142M vs. CDXC (32.2M). ORMP has less debt than CDXC: ORMP (429K) vs CDXC (2.9M). CDXC has higher revenues than ORMP: CDXC (91.7M) vs ORMP (0).
CDXCORMPCDXC / ORMP
Capitalization454M91.9M494%
EBITDA1.95M9.44M21%
Gain YTD11.970-5.785-207%
P/E Ratio297.0020.731,433%
Revenue91.7M0-
Total Cash32.2M142M23%
Total Debt2.9M429K675%
FUNDAMENTALS RATINGS
CDXC vs ORMP: Fundamental Ratings
CDXC
ORMP
OUTLOOK RATING
1..100
1368
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
66
Overvalued
PROFIT vs RISK RATING
1..100
85100
SMR RATING
1..100
8485
PRICE GROWTH RATING
1..100
3556
P/E GROWTH RATING
1..100
5555
SEASONALITY SCORE
1..100
7531

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (66) in the Pharmaceuticals Other industry is in the same range as CDXC (94) in the Chemicals Specialty industry. This means that ORMP’s stock grew similarly to CDXC’s over the last 12 months.

CDXC's Profit vs Risk Rating (85) in the Chemicals Specialty industry is in the same range as ORMP (100) in the Pharmaceuticals Other industry. This means that CDXC’s stock grew similarly to ORMP’s over the last 12 months.

CDXC's SMR Rating (84) in the Chemicals Specialty industry is in the same range as ORMP (85) in the Pharmaceuticals Other industry. This means that CDXC’s stock grew similarly to ORMP’s over the last 12 months.

CDXC's Price Growth Rating (35) in the Chemicals Specialty industry is in the same range as ORMP (56) in the Pharmaceuticals Other industry. This means that CDXC’s stock grew similarly to ORMP’s over the last 12 months.

CDXC's P/E Growth Rating (55) in the Chemicals Specialty industry is in the same range as ORMP (55) in the Pharmaceuticals Other industry. This means that CDXC’s stock grew similarly to ORMP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXCORMP
RSI
ODDS (%)
Bullish Trend 11 days ago
84%
N/A
Stochastic
ODDS (%)
Bullish Trend 11 days ago
80%
Bullish Trend 11 days ago
82%
Momentum
ODDS (%)
Bullish Trend 11 days ago
68%
Bullish Trend 11 days ago
80%
MACD
ODDS (%)
N/A
Bearish Trend 11 days ago
67%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
81%
Bearish Trend 11 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
83%
Bearish Trend 11 days ago
84%
Advances
ODDS (%)
Bullish Trend 11 days ago
80%
Bullish Trend 13 days ago
82%
Declines
ODDS (%)
Bearish Trend 19 days ago
83%
Bearish Trend 11 days ago
84%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 11 days ago
79%
N/A
View a ticker or compare two or three
Ad is loading...
CDXC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PYXS1.500.03
+2.04%
Pyxis Oncology
CTTAY6.860.09
+1.33%
Continental AG
NPSNY39.440.51
+1.32%
Naspers Ltd.
ILIKF0.25N/A
+1.00%
Ilika PLC.
SPGYF6.91-0.02
-0.36%
Whitecap Resources, Inc.

CDXC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXC has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXC jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXC
1D Price
Change %
CDXC100%
+5.13%
AXON - CDXC
43%
Loosely correlated
+1.37%
EDIT - CDXC
36%
Loosely correlated
-1.61%
ORMP - CDXC
35%
Loosely correlated
-1.72%
AMRN - CDXC
35%
Loosely correlated
+0.72%
CYTK - CDXC
35%
Loosely correlated
-2.66%
More